Oramed Initiates Recruitment For ORMD-0801 Clinical Trial In Type I Diabetes

Oramed Pharmaceuticals has initiated patient recruitment for a new clinical trial of its orally-ingestible insulin capsule, ORMD-0801, for patients with Type I diabetes in Israel.

Prior clinical studies have shown that ORMD-0801 administered to Type I diabetes patients just prior to a meal effectively kept their blood glucose levels stable. ORMD-0801 is currently initiating Phase II trials on patients with Type II diabetes under an IND application with the FDA.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Israel

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.